SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is a top trending stock as investors analyze its J.P. Morgan Healthcare Conference presentation for critical updates on its oral VK2735 program and commercialization plans, reinforced by a recent Chief Commercial Officer hire and the completion of its obesity maintenance study enrollment. The community is sharply divided between bullish expectations for a significant partnership or buyout, driven by the drug's perceived 'best-in-class' potential, and concerns over stock price suppression and management's strategy within the highly competitive metabolic market.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending amid discussions surrounding potential new tariffs on countries trading with Iran and a reported DOJ probe into Fed Chair Powell, sparking debate on market stability and the independence of the central bank. Despite these headlines, a strong bullish sentiment prevails among many, emphasizing buying opportunities during dips and highlighting the market's resilience. The community is actively discussing whether the market can sustain its upward momentum given these geopolitical and regulatory concerns, often with frustration from those anticipating a significant pullback.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is trending due to strategic announcements around its ambitious "Meta Compute" AI infrastructure buildout, which includes securing multi-gigawatt nuclear energy agreements to power future data centers. This aggressive AI push, alongside reported layoffs in the Reality Labs division, is sparking mixed community reactions regarding the scale of investment versus potential returns. Investors are keenly observing these developments as Meta intensifies its position in the global AI race, with many awaiting further clarity on the long-term vision.

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Travere Therapeutics Inc

Travere Therapeutics is trending sharply lower following the FDA's request for additional clarification on the clinical benefit of FILSPARI for FSGS, a development that has caused significant market jitters ahead of its PDUFA decision. While many in the community are concerned this signals a potential Complete Response Letter, a notable counter-narrative suggests the sell-off is an overreaction, pointing to the company's strong commercial execution for FILSPARI in IgAN and solid financial standing as reasons to buy the dip.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending as the U.S. recommendation to add Duchenne Muscular Dystrophy to the newborn screening panel significantly broadens the long-term market for its Elevidys gene therapy. While recent preliminary financial updates led to stock volatility, the community is actively discussing perceived undervaluation and the substantial pipeline potential, particularly in light of expanding early patient identification.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Teladoc Health is trending amid intense community debate, fueled by its ongoing underperformance and deep frustration with current management's ability to deliver sustained profitability. However, many investors remain bullish, highlighting the company's position as a global leader in virtual care and its potential to capture a significant share of the rapidly expanding AI healthcare market. Recent partnerships, such as with TytoCare for at-home diagnostics, and anticipation around the $50 billion Rural Health Transformation Program are seen as key catalysts, driving speculation of a significant long-term rebound for the stock.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is actively trending amid high community anticipation for potential major news, particularly concerning its GaN and SiC power solutions for next-generation AI data centers and a possible collaboration with NVIDIA. Investors are keenly discussing its substantial short interest, fueling speculation of a significant short squeeze alongside bullish technical setups.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo Inc. is actively trending following a significant agreement with Meta Platforms to develop 1.2 gigawatts of nuclear energy for its AI data centers, with its CEO also set to appear on CNBC. While bulls view this as a crucial validation for advanced nuclear technology and a catalyst for future partnerships, skeptics point to the company's lack of revenue, unapproved designs, and notable insider selling against a distant commercial timeline. The market remains divided on whether the growing demand for AI power justifies Oklo's current valuation, especially as the community awaits overdue plutonium awards.

Duolingo, Inc. is a language-learning website and mobile application, which engages in the development of a free language learning website and crowd sourced text translation platform. It offers Duolingo for Schools, a free, web-based tool that aims to make it easier for teachers to use the Duolingo platform in a structured learning environment, and English Test, an online, on-demand assessment of English proficiency. The company was founded by Luis von Ahn and Severin Hacker in 2011 and is headquartered in Pittsburgh, PA.

Duolingo Inc - Ordinary Shares - Class A

Duolingo Inc

Duolingo is trending amid a recent CFO transition and its reaffirmed commitment to prioritizing user growth and product innovation, despite strong preliminary Q4 metrics. The stock's significant decline has sparked a heated debate, with bulls viewing it as an oversold opportunity supported by strong fundamentals and AI integration, while bears argue the business model is vulnerable to free AI alternatives and cite ongoing chart weakness.

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Louisville, CO.

Biodesix Inc

BDSX is trending due to strong preliminary Q4 and full-year 2025 results, which reported significant revenue growth and reaffirmed guidance for Adjusted EBITDA positivity. The community is actively discussing the stock's explosive volume and price action, with many speculating on continued momentum and a potential short squeeze. However, some investors express caution, pointing to the company's cash position and potential future dilution within the volatile biotech sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The company announced its current Chief Financial Officer, Matt Skaruppa, would be stepping down and be replaced by Gillian Munson, Board Member and Chair of the Audit Committee.</li><li>The company said that the transition would happen on February 23, 2026.&nbsp;</li><li>In addition, Duolingo provided a preliminary update on operating metrics for the fourth quarter, indicating a DAU growth of about 30% year over year and bookings at or slightly above the high end of its previously announced guidance range.</li></ul>Shares of language-learning app Duolingo Inc. (DUOL) closed over 8.4% lower on Monday after the company announced the current Chief Financial Officer, Matt Skaruppa, will step down and will be replaced by Board Member and Chair of Audit Committee Gillian Munson.The company said that the transition would happen on February 23, 2026.In addition, Duolingo provided a preliminary update on operating metrics for the fourth quarter ended Dec. 31, 2025.Shares of DUOL traded slightly higher in after-market hours, climbing 0.28% at the time of writing.<h2 class="st-heading-2">New Era</h2>Skaruppa will step down after almost six years with the company, during which Duolingo went public.“Duolingo has been the most rewarding chapter of my career,” Skaruppa said in the statement, highlighting his experience of taking the company public, and building a finance organization that matched its creativity.Meanwhile, Munson will step up as the CFO after having served on the company’s Board of Directors since 2019. Her experience includes being CFO of Vimeo, Iora Health, Inc. and XO Group Inc., in addition to other leadership positions."Having worked closely with leadership as a Board member, I’ve developed deep respect for Duolingo’s culture, operating discipline, and momentum. Few companies combine this level of engagement and impact with strong financial fundamentals, and I’m honored to step into the CFO role to help advance Duolingo’s long-term mission to bring the best education to the world,” Munson said.<h2 class="st-heading-2">Financial Update</h2>In addition to the CFO transition, Duolingo also announced a preliminary update on operating metrics for the fourth quarter ended Dec. 31, 2025. The company said that its preliminary results indicated a fourth quarter DAU growth of about 30% year over year and bookings at or slightly above the high end of its previously announced guidance range of $329.5 million - $335.5 million.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/DUOL">DUOL shares</a> jumped to ‘extremely bullish’ from ‘bullish’ territory over the past day amid ‘extremely high’ message volumes.One bullish user noted the drop despite the new CFO announcement and said that they would be ‘buying this dip.’<stembedurl>https://stocktwits.com/Mj6095/message/641559882</stembedurl>&nbsp;Another user called the drop in share prices an ‘overreaction’.<stembedurl>https://stocktwits.com/drbob512/message/641565257</stembedurl>&nbsp;Shares of DUOL have lost over 48% of their value in the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

A laptop keyboard and Duolingo on App Store displayed on a phone screen are seen in this illustration photo. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

Duolingo Shares Declined After CFO Transition Announcement — Retail Says ‘Buying This Dip’ 

Duolingo shares ended in red on Monday after the company announced a CFO transition and reported a preliminary update on operating metrics.

Equity

Duolingo (NASDAQ:DUOL) Sets New 52-Week Low - Here's Why

Duolingo (NASDAQ:DUOL) Reaches New 12-Month Low - Here's What Happened...

Stocks making the biggest moves midday: Citigroup, Abercrombie, Vistra, Duolingo and more

These are some of the stocks posting the largest moves in midday trading...

Duolingo Shares Hit Fresh Lows: What's Driving The Weakness?

Duolingo, Inc. (NASDAQ:DUOL) shares are trading lower, hitting 52-week lows. The company on Monday announced a CFO transition.read more...

BMNR vs. DUOL: Which Technology Services Stock Has More Upside Now?

BMNR has surged 298% since going public. fueled by Ethereum accumulation and a shareholder-friendly strategy.

Robeco Institutional Asset Management B.V. Sells 18,059 Shares of Duolingo, Inc. $DUOL

Robeco Institutional Asset Management B.V. reduced its position in shares of Duolingo, Inc. (NASDAQ:DUOL - Free Report) by 62.7% in the 3rd quarter, according to its most recent filing with the...

16 Analysts Assess Duolingo: What You Need To Know

Is Trending Stock Duolingo, Inc. (DUOL) a Buy Now?

Duolingo (DUOL) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Will Chegg's 60% CapEx Cut in 2026 Free Up Enough Fuel for Growth?

Will CHGG's 60% capex cut in 2026 unlock cash for skilling growth as it pivots away from legacy academics?

Chegg Stock Trades at a Discount: Should Investors Buy It Yet?

Is CHGG's discounted valuation signaling an opportunity as it restructures around skilling, B2B partnerships and tighter cost discipline?


Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

Stocktwits

Stocktwits Polls

Traders are intensely debating whether advancing AI language tools will render the company's core product obsolete or enhance its offerings, causing concern.

Many investors view the stock's recent drop to a new 52-week low as an overreaction, indicating a potential buying opportunity, especially around the $130-$160 range.

The company's stock experienced a significant drop following the announcement of its CFO's upcoming departure and replacement in early 2026.

A segment of the community expresses strong bearish sentiment, declaring the company's business model is fundamentally flawed and heading for further declines.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	$0.83	--	--	N/A
Q3 '25	$0.76	$5.95	684.41%	BEAT
Q2 '25	$0.59	$0.91	55.10%	BEAT
Q1 '25	$0.51	$0.72	39.86%	BEAT
Q4 '24	$0.48	--	--	N/A

DUOL
Duolingo Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest DUOL News

DUOLDuolingo Inc